Clinical Trials Logo

Toxemia clinical trials

View clinical trials related to Toxemia.

Filter by:

NCT ID: NCT03048903 Recruiting - Sepsis Clinical Trials

The Effect of Rhubarb on Sepsis and Post-traumatic Gastrointestinal Function Failure

Start date: February 2016
Phase: Phase 2
Study type: Interventional

Random grouping by computer, divided into two groups, a group of rhubarb treatment group, another group for the placebo group.

NCT ID: NCT03044223 Recruiting - Sepsis Clinical Trials

Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis

MIPSA
Start date: August 2014
Phase:
Study type: Observational

The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype predominates in blood monocytes in critically ill patients with PSA-sepsis, and whether the severity of sepsis and outcome is associated with distinct monocyte phenotype and function.

NCT ID: NCT03037281 Completed - Sepsis Clinical Trials

Release of Nociceptin From Granulocytes in Sepsis

Start date: April 7, 2016
Phase:
Study type: Observational

Nociceptin is a protein found in the body, with a number of functions in the central nervous system, blood vessels and the gut. There is evidence that it may have a role in controlling the immune response to infection, and may act as a link between the brain and immune system. In infection, or after surgery, there is an increase in nociceptin, and subjects greater elevations of nociceptin have a poorer outcome. There is evidence that cells of the immune system may produce nociceptin, although it is not yet known which cells are capable of producing it, and what "switches on" production. This study aims to determine 1. Which cells of the immune system can produce nociceptin 2. If there is a difference in the ability to produce nociceptin between healthy volunteers and patients with severe infections

NCT ID: NCT03029039 Completed - Severe Sepsis Clinical Trials

Platelet-associated Inflammation in Severe Sepsis

PlatISSep
Start date: February 2, 2017
Phase:
Study type: Observational [Patient Registry]

Sepsis represents a serious public health issue characterized by a complex inflammatory response. In addition to their hemostatic role, platelets display inflammatory functions by secreting a variety of immunomodulatory factors and interacting with circulating immune cells. The investigators postulate that, in severe sepsis, platelets become activated and release amounts of different soluble inflammatory molecules that contribute to sepsis-associated inflammation. First, the investigators propose to assess whether severe sepsis impairs the ability of platelets to release soluble CD40L (sCD40L), an powerful platelet-derived immunomodulatory molecule, in ICU patients with S. aureus documented infection, ICU patients with documented infection involving other bacterial species, compared to ICU patients with inflammation of noninfectious origin and healthy blood donors. Then, the investigators wish to assess whether the bacterial species affects the release of platelet sCD40L and by an extensive screening of platelet soluble factors, the investigators propose to set up profiles of inflammatory molecules associated with the type of infection. Finally, the investigators will analyze platelets' activation state and their association with circulating immune, according to the type of infection. Therefore, this project is expected to assess to which extent the platelet inflammatory function is super-activated in severe sepsis and to identify new platelet-related biomarkers of sepsis.

NCT ID: NCT03019965 Completed - Sepsis Clinical Trials

Efficacy of Betalactam Antibiotics in Prolonged Infusion Compared to Intermittent in Pediatric Patients With Sepsis

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

This study evaluates the efficacy and safety of the administration of betalactam antibiotics in prolonged infusion compared to intermittent infusion in children with sepsis. Half of participants will receive piperacillin/tazobactam, imipenem or meropenem in continuous or extended infusion, while the other half will receive piperacillin/tazobactam, imipenem or meropenem in intermittent infusion.

NCT ID: NCT03015584 Completed - Sepsis Clinical Trials

Systems Biology Approach to Cognitive Impairment After SepsiS

CASS
Start date: June 2015
Phase:
Study type: Observational

This study will use systems biology techniques, especially RNA-seq, to understand cognitive impairment after sepsis requiring an intensive care unit (ICU) admission.

NCT ID: NCT03015454 Completed - Sepsis Clinical Trials

An Algorithm Driven Sepsis Prediction Biomarker

Start date: December 2016
Phase: N/A
Study type: Interventional

A sepsis early warning predictive algorithm, InSight, has been developed and validated on a large, diverse patient cohort. In this prospective study, the ability of InSight to predict severe sepsis patients is investigated. Specifically, InSight is compared with a well established severe sepsis detector in the UCSF electronic health record (EHR).

NCT ID: NCT03010410 Enrolling by invitation - Sepsis Clinical Trials

Platelet Immune Responses in Aging and Influenza and Sepsis (INVACS)

Start date: December 21, 2014
Phase:
Study type: Observational

Aging is associated with immunosenescence and impaired host defense mechanisms, contributing to influenza-related morbidity and mortality. Preliminary data demonstrate that the platelet transcriptome is markedly different between healthy subjects and influenza patients. Interferon-induced transmembrane proteins (IFITM) family members are among the transcripts significantly increased in platelets during influenza and expression of IFITM-3 is impaired in elderly subjects, a pattern associated with increased mortality. This study will build on these data and investigate if aging influences the expression of platelet IFITM family members in patients with influenza and sepsis. This study will prospectively determine if aging alters the induction of (IFITMs) in platelets from hospitalized influenza and sepsis patients. The study will also determine if diminished expression of IFITM family members correlates with an increased risk of adverse outcomes in older influenza and sepsis patients.

NCT ID: NCT02988414 Completed - Bacteremia Clinical Trials

Diagnosis of Bacteremia/Septicemia and Culture Negative Endocarditis by the Karius Sequencing-Based Infectious Disease Diagnostic Assay

Start date: July 2016
Phase:
Study type: Observational

Prospective study at Duke University Hospital comparing the Karius Infectious Disease Diagnostic Sequencing Assay to blood culture results in admitted patients with bacteremia/septicemia.

NCT ID: NCT02980588 Not yet recruiting - Sepsis Clinical Trials

The Effects of SGC on Glucose Control in Critically Ill Patients With Sepsis

Start date: December 2016
Phase: N/A
Study type: Interventional

Poorly glycemic control in critically ill patients can increase their mortality, while safe and efficient glucose control is laborious and time-consuming. The Space Glucose Control which is installed with eMPC(enhanced Model Predictive Control) can get the blood glucose target range safely and effectively through regulating insulin dose rate, and decrease the glucose variability. This study is a random controlled trial involving the patients with sepsis in intensive care unit in order to evaluate the difference of safety and efficacy of blood glucose control between SGC directed and conventional treatment. At last, the trial results can determine whether the Space Glucose Control can control blood glucose safely and effectively in the patients with sepsis in intensive care units.